Professor Solomon Diamond discusses how his noninvasive head probe for neurovascular coupling assessment will make it possible to diagnose and track Alzheimer’s disease.

rudramani.com – Herbs that halt and reverse AD Alzheimer’s disease is a devastating disorder of the brain’s nerve cells that impairs memory, thinking, and behavior. Shilajit & Withania seems to benefit Alzheimer’s patients in a truly surprising manner. Alzheimer’s disease (AD), also known in medical literature as Alzheimer disease, is the most common form of dementia. There is no cure for the disease, which worsens as it progresses, and eventually leads to death. It was first described by German psychiatrist and neuropathologist Alois Alzheimer in 1906 and was named after him.[1] Most often, AD is diagnosed in people over 65 years of age although the less-prevalent early-onset Alzheimer’s can occur much earlier. In 2006, there were 26.6 million sufferers worldwide. Alzheimer’s is predicted to affect 1 in 85 people globally by 2050.[3] Although Alzheimer’s disease develops differently for every individual, there are many common symptoms.[4] Early symptoms are often mistakenly thought to be ‘age-related’ concerns, or manifestations of stress.[5] In the early stages, the most common symptom is difficulty in remembering recent events. When AD is suspected, the diagnosis is usually confirmed with tests that evaluate behaviour and thinking abilities, often followed by a brain scan if available.[6] As the disease advances, symptoms can include confusion, irritability and aggression, mood swings, trouble with language, and long-term memory loss. As the sufferer declines they …

Approximately 7 million people suffer from Parkinson’s and Alzheimer’s diseases in the United States alone. Prof. Moussa BH Youdim, Director of the Eve Topf and US National Parkinson Foundation Centers of Excellence in Technion’s Rappaport Faculty of Medicine, discusses the neurorestoration properties of the breakthrough drugs being developed in his laboratory that promise hope for millions of Parkinson’s and Alzheimer’s patients throughout the world. Interview filmed in April 2011.

Alzheimer’s disease is an extremely devastating neurodegenerative disorder that is the number one cause of dementia in patients over the age of 65. Most research on Alzheimer’s disease has focused on treating the later stage symptoms of the illness. Using antibody treatments, scientists have been even able to almost eliminate the aggregates of proteins that tend to form in the brains of Alzheimer’s patients. However, this has not been able to halt the progression of the disease. This study aims to explore a promising new avenue of viewing the causation of Alzheimer’s disease that can potentially be applied towards diagnosing this illness during its early stages and conquering it once and for all. I created this video as a summary of my research for the Google Science Fair. If you thought that this concept was interesting, please comment or vote for my project. Thanks!

It was believed that Alzheimer’s disease results when a particular protein randomly detaches itself from brain cells, which are usually connected, and to form tangles. It was thought this happened in many parts of the brain at the same time. But, new research is challenging this view. The latest research on the subject suggests the protein actually spreads cell by cell through the brain in a predictable way. The new findings are an important step in the battle against the disease. Al Jazeera’s Tarek Bazley reports.

The Search for Medicine for Down’s Syndrome Towards an International Research Alliance September 17th 2011 The Wellcome Trust Conference Centre Genome Campus Hinxton, Cambridge, UK. Program sponsored by The Down’s Syndrome Research Foundation UK www.dsrf-uk.org and a grant from Alzheimer’s Research UK www.alzheimersresearchuk.org Professor Potter, PhD, – Director of the Florida Alzheimer’s Disease Research Center (NIA), AAAS Fellow. Professor and Eric Pfeiffer Chair for Research on Alzheimer’s Disease. President of the USF Tampa Faculty Senate, Department of Molecular Medicine. Eric Pfeiffer Suncoast Alzheimer’s Center, USF Health Byrd Alzheimer Institute. University of South Florida College of Medicine, 4001 E. Fletcher Avenue. Tampa FL 33613 Down Syndrome and Alzheimer’s disease: Two Sides of the Same Coin Trisomy 21 Down syndrome (DS) and Alzheimer’s disease (AD) share many pathological and mechanistic features that provide insights into the pathogenesis of the two diseases and suggest novel approaches to therapy. The earliest connection between DS and AD came with the recognition that all DS individuals develop AD pathology by age 20 and most develop dementia by age 50. The fact that the gene encoding the Alzheimer Amyloid Precursor Protein (APP) resides on chromosome 21 further linked two disorders. These results led us to propose a unifying hypothesis for DS and AD in which Alzheimer’s is a cell cycle disease in which patients develop trisomy 21 cells throughout …

Case Western Reserve Researchers Discover FDA-approved Drug Rapidly Clears Amyloid from the Brain and Reverses Cognitive and Memory Defects. School of Medicine Neurosciences Gary Landreth, PhD Paige Cramer

Told by Steven M. Paul, MD Director, Helen and Robert Appel Alzheimer’s Disease Research Institute Professor of Neuroscience Professor of Pharmacology Professor of Psychiatry Visit weill.cornell.edu for more information.

geriatricresearch.medicine.dal.ca A short film explaining new insights into repetitive talk in Alzheimer’s disease patients. From the Geriatric Medicine Research Unit, in Halifax, Nova Scotia, Canada.

There is no cure for Alzheimer’s, but there are steps to slow its progression. www.WatchMojo.com learns about how Alzheimer’s affects sufferers and their families, about the treatment options available to manage it and about recent progress in research into the disease.